$65 (Future Members)
Thank you to our sponsor Kilpatrick Townsend & Stockton LLP
Sponsorships are available! Contact Amanda Tran, Vice President, Membership Services at firstname.lastname@example.org for more details.
The United States is currently in the midst of an epidemic of prescription opioid-drug abuse. Last year alone, 20,000 people in the US died from overdose of prescription opioid drugs. While few new pain medicines have emerged in the last few years, great strides have been made in understanding the complex biology of pain. Scientists have discovered new pain pathway targets with the potential for designing effective and safe medicines with fewer off-target effects. New pain drugs in development have the potential to solve the problems of opioid drug addiction and provide safer alternatives.
Improvements that make preclinical studies more predictive of clinical success are also opening up new opportunities. At the same time, drug developers now have new approaches to designing pain drug trials to demonstrate therapeutic efficacy more precisely, potentially reducing the magnitude of placebo effects and paving the way for an era of personalized pain medicine. This symposium will discuss several novel therapeutic approaches based on novel pain targets and mechanisms and review novel clinical approaches for development.
Luke Timmerman, Timmerman Report
Miroslav Backonja, M.D., Professor, University of Washington, Department of Neurology
Charles Chavkin, Ph.D., Professor, University of Washington School of Medicine, Department of Pharmacology
Jeffrey Herz, Ph.D., President and CEO, Algomedix Inc.
Shawn Iadonato, Ph.D. CEO, Kineta